Compare Abeona Therapeutics Inc (ABEO) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Yum! Brands, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Yum! Brands, Inc. trades at $165.3 (market cap $46.16B). The key difference: Yum! Brands, Inc. is far larger — about 123.6× Abeona Therapeutics Inc's market cap, and Yum! Brands, Inc. pays a 1.79% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | YUM | |
|---|---|---|
Market Cap | $373.32M | $46.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $168.16 |
52-Week Low | $4.17 | $138.21 |
Enterprise Value | $228.22M | $57.43B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
YUM trades at $167.49, up 1.68% today, near its consensus price target of $174.00. The stock shows a bullish technical trend with strong moving averages, though RSI indicates potential overbought conditions. Fundamentals are solid with revenue growth from $7.5B in 2024 to $8.2B in 2025 and a net income margin of 20.48%. Recent news highlights the $2.7 billion sale of Pizza Hut, aimed at streamlining operations and funding a $4 billion share repurchase, signaling strategic focus on KFC and Taco Bell.
The outlook for YUM is cautiously optimistic, supported by earnings beats and strategic divestiture, but high debt levels and competitive pressures pose risks. Analyst consensus leans hold with a 37.25% buy rating, suggesting moderate upside potential. Investors should weigh the benefits of capital returns against execution risks in a challenging consumer discretionary environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
